基宁-卡利克林系统:对心力衰竭的新视角
Keivan Mohammadi1, Davood Shafie2, Newsha Ghomashi3
1Shahid Chamran Heart Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Heart failure reviews
|February 21, 2024
概括
基宁-卡利克林系统 (KSS) 在心力衰竭 (HF) 中起着双重作用. 阻止KSS可能是减少心脏重塑和改善HF症状的有希望的策略.
科学领域:
- 心血管医学 心血管医学
- 身体生理学 身体生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 是一种影响心脏功能和生活质量的重大临床问题.
- 复杂的酸级联 (kinin-kallikrein) 系统 (KSS) 越来越多地被认为与高频率有关.
- 在KSS组件中的异常与增加的HF风险有关.
研究的目的:
- 为了研究金-卡利克林系统 (KSS) 在心力衰竭 (HF) 病理生理学中的多方面的作用.
- 探索KSS封锁作为管理HF进展和症状的治疗策略的潜力.
主要方法:
- 关于基宁-卡利克林系统 (KSS) 和其组成部分,包括布拉迪基宁 (BK),B1和B2受体以及卡利克林的现有文献的综述.
- 对KSS激活对心脏功能,炎症,凝血,血压和血管透性的生理影响的分析.
- 在高风的背景下,检查KSS和氨酸-血管酶-氨酸系统 (RAAS) 之间的相互作用.
主要成果:
- 基宁-卡利克林系统 (KSS) 的激活表现出双重效应:在急性心脏损伤中有益 (例如,通过布拉迪基宁的血管扩张),但在慢性HF中有害 (例如,炎症,原体损失).
- 卡利克林的活性可以导致有益的布拉迪基宁效应和有害的血管激素II上调,促进血管收缩和液体保留.
- 长时间的KSS激活有助于心脏原体的损失和重塑,由常规的氨酸-氨酸-阿尔多斯特系统 (RAAS) 抑制剂加剧.
结论:
- 基宁-卡利克林系统 (KSS) 阻塞是一种潜在的治疗策略,可以缓解心脏重塑并改善心力衰竭 (HF) 的结果.
- 抑制KSS可能会减轻免疫系统激活和HF组织损伤的有害影响.
- 需要进一步的研究,以了解卡利克林抑制剂在慢性肺炎中的长期益处,考虑到布拉迪基宁的复杂作用.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
638
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
638
01:22Heart Failure Drugs: β-Blockers
340
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
92
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
92